Research programme: drug discovery - Actelion Pharmaceuticals /Vipergen

Drug Profile

Research programme: drug discovery - Actelion Pharmaceuticals /Vipergen

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator Vipergen ApS
  • Developer Actelion Pharmaceuticals; Vipergen ApS
  • Class Small molecules
  • Mechanism of Action Protein modulators; Protein-protein interaction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 21 Dec 2015 Early research in Undefined indication in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top